Werewolf Therapeutics, Inc.

5mon ago, source: CNN

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

20d ago, source:

Werewolf Therapeutics, Inc. is developing modified cytokines for cancer treatment, including WTX-124 and WTX-330. Click for ...

Buy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline Potential

6d ago, source:

In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Werewolf Therapeutics (HOWL – ...

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy

9d ago, source: Zacks.com on MSN

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Werewolf Therapeutics Expands Offering with $25M Stock Sale

2mon ago, source: TipRanks on MSN

Werewolf Therapeutics (HOWL) has released an update. Werewolf Therapeutics, Inc. has filed a prospectus supplement for the ...

Werewolf Therapeutics Inc (HOWL) Stock: A SWOT Analysis

9d ago, source: newsheater

Smart investors will not be hesitating on this one! Werewolf Therapeutics Inc (NASDAQ: HOWL)’s stock price has gone rise by 17.06 in comparison to its previous close of 4.69, however, the company has ...

Buy Rating for Werewolf Therapeutics: Innovation and Financial Stability Signal Promising Future in Immunotherapy

22d ago, source: Business Insider

Werewolf Therapeutics (HOWL) Company Description: Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body ...

How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%

1mon ago, source: Nasdaq

Shares of Werewolf Therapeutics, Inc. (HOWL) have gained 7% over the past four weeks to close the last trading session at $6.55, but there could still be a solid upside left in the stock if short ...

Werewolf Therapeutics Inc HOWL

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Werewolf Therapeutics Inc (HOWL)

2d ago, source: Investing

On Wednesday, JMP Securities initiated coverage on Werewolf Therapeutics Inc. (NASDAQ:HOWL) stock with a Market Outperform rating and set a price target of $12.00. The firm ...

Werewolf Therapeutics Inc HOWL

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...